In 2015, the 340B Drug Discount Program saved healthcare providers $6 billion on drug acquisition costs. While the program aims to make pharmaceutical and clinical care affordable and accessible to low-income patients; there is evidence that some participating entities are exploiting its discounts for profit. Since close...
Recently, Congress introduced reformed 340B eligibility requirements and has requested more comprehensive reporting on how hospitals utilize savings from the program. Republican Representative Chris Collins initiated the legislative push to overhaul the 340B Drug Discount Program and expects prompt consideration on the House floor. Collins views...
Thirty years of claims processing experience makes SCL 340B CARE the ideal partner, providing an elite set of services for clients throughout the country. We are the leader in 340B program administration and continually build on this reputation through the constant expansion and excellence of...
A recent report from the National Academies of Sciences, Engineering, and Medicine shows that the need for effective and affordable medicines is being underserved by the biopharmaceutical sector. The report is composed of eight (8) recommendations and twenty-seven (27) strategies aimed to improve prescription drug...
Our healthcare industry is evolving into a fee-for-value payment system, which promotes value and efficiency. This new system increases the quality of care and focuses on the outcome of treatment for its patients. This industry improvement is now encountering astronomical price increases of prescription drugs...